J Cancer
2011; 2:324-328.
doi:10.7150/jca.2.324 This volumeCite
Short Report
Targeting EGFR in Triple Negative Breast Cancer
Naoto T. Ueno1,2, Dongwei Zhang1,2 ✉
1. Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2. Department of Breast Medical Oncology, Morgan Welch Inflammatory Breast Cancer Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
✉ Corresponding author: Prof. Naoto T. Ueno, Phone: 713-792-8754; Fax: 713-794-4385; E-mail: nuenoorg
Citation:
Ueno NT, Zhang D. Targeting EGFR in Triple Negative Breast Cancer. J Cancer 2011; 2:324-328. doi:10.7150/jca.2.324. https://www.jcancer.org/v02p0324.htm
Our preliminary data show that erlotinib inhibits Triple-negative breast cancer (TNBC) in a xenograft model. However, inhibition of metastasis by erlotinib is accompanied by nonspecific effects because erlotinib can inhibit other kinases; thus, more direct targets that regulate TNBC metastasis need to be identified to improve its therapeutic efficacy.
Ueno, N.T., Zhang, D. (2011). Targeting EGFR in Triple Negative Breast Cancer. Journal of Cancer, 2, 324-328. https://doi.org/10.7150/jca.2.324.
ACS
Ueno, N.T.; Zhang, D. Targeting EGFR in Triple Negative Breast Cancer. J. Cancer 2011, 2, 324-328. DOI: 10.7150/jca.2.324.
NLM
Ueno NT, Zhang D. Targeting EGFR in Triple Negative Breast Cancer. J Cancer 2011; 2:324-328. doi:10.7150/jca.2.324. https://www.jcancer.org/v02p0324.htm
CSE
Ueno NT, Zhang D. 2011. Targeting EGFR in Triple Negative Breast Cancer. J Cancer. 2:324-328.